New combo aims to shrink Hard-to-Treat tumors
Disease control
Not yet recruiting
This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have stopped responding to standard care. About 227 adults with various cancers, including lung, breast, and colorectal, will receive the combination to se…
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC